pyrazinamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2328	98-96-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pyrazinecarboxamide pyrazinamide 2-pyrazinecarboxamide pyramizade alpha-pyrazinamide zinamide	A pyrazine that is used therapeutically as an antitubercular agent. Molecular weight: 123.12 Formula: C5H5N3O CLOGP: -0.68 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 68.87 ALOGS: -0.12 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

pyrazinecarboxamide
pyrazinamide
2-pyrazinecarboxamide
pyramizade
alpha-pyrazinamide
zinamide

A pyrazine that is used therapeutically as an antitubercular agent.

Molecular weight: 123.12
Formula: C5H5N3O
CLOGP: -0.68
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 68.87
ALOGS: -0.12
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.50	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	15 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1.60 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	243.67 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	90 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
June 3, 1971	FDA	DAVA PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	774.94	24.33	260	9154	33576	63446032
Paradoxical drug reaction	519.37	24.33	121	9293	4031	63475577
Drug-induced liver injury	403.55	24.33	169	9245	40053	63439555
Acute hepatic failure	376.40	24.33	130	9284	18197	63461411
Drug resistance	340.63	24.33	128	9286	22805	63456803
Tuberculoma of central nervous system	273.58	24.33	47	9367	300	63479308
Hepatotoxicity	219.76	24.33	108	9306	36933	63442675
Immune reconstitution inflammatory syndrome	218.44	24.33	66	9348	6018	63473590
Hepatitis	206.62	24.33	106	9308	39682	63439926
Immune reconstitution inflammatory syndrome associated tuberculosis	204.14	24.33	37	9377	333	63479275
Jaundice	149.11	24.33	77	9337	29174	63450434
Pulmonary tuberculosis	145.11	24.33	45	9369	4472	63475136
Drug interaction	132.25	24.33	166	9248	228965	63250643
Hepatic encephalopathy	131.97	24.33	53	9361	11229	63468379
Tuberculosis	108.51	24.33	46	9368	11165	63468443
Pancreatitis haemorrhagic	90.77	24.33	20	9394	513	63479095
Pyrexia	85.63	24.33	204	9210	470274	63009334
Disseminated tuberculosis	85.55	24.33	27	9387	2840	63476768
Neuropathy peripheral	84.73	24.33	94	9320	113573	63366035
Eosinophilia	82.92	24.33	48	9366	22708	63456900
Alanine aminotransferase increased	81.13	24.33	88	9326	103682	63375926
Aspartate aminotransferase increased	73.08	24.33	78	9336	90199	63389409
Distributive shock	67.27	24.33	19	9395	1364	63478244
Electrocardiogram QT prolonged	60.15	24.33	58	9356	59472	63420136
Lymphadenopathy	60.05	24.33	48	9366	38410	63441198
Transaminases increased	59.61	24.33	44	9370	31323	63448285
Meningitis tuberculous	57.08	24.33	14	9400	579	63479029
Fatigue	53.53	24.33	33	9381	887995	62591613
Hepatitis toxic	51.30	24.33	19	9395	3234	63476374
Aspergillus infection	49.13	24.33	24	9390	8069	63471539
Oedematous pancreatitis	47.33	24.33	12	9402	569	63479039
Oedematous kidney	47.06	24.33	9	9405	111	63479497
Hepatocellular injury	46.68	24.33	36	9378	27345	63452263
Drug level decreased	46.62	24.33	23	9391	7896	63471712
Hepatitis fulminant	46.55	24.33	18	9396	3446	63476162
Pain	45.31	24.33	27	9387	740601	62739007
Multiple organ dysfunction syndrome	44.08	24.33	48	9366	56704	63422904
Rash maculo-papular	43.90	24.33	37	9377	31859	63447749
Fall	43.62	24.33	4	9410	392330	63087278
Gamma-glutamyltransferase increased	41.82	24.33	37	9377	33994	63445614
Hepatic function abnormal	40.96	24.33	38	9376	37104	63442504
Hepatic failure	40.33	24.33	37	9377	35619	63443989
Cholestatic liver injury	40.26	24.33	15	9399	2595	63477013
Optic neuropathy	40.05	24.33	14	9400	2018	63477590
Multiple-drug resistance	39.59	24.33	18	9396	5152	63474456
Toxic optic neuropathy	37.02	24.33	8	9406	187	63479421
Immunosuppressant drug level decreased	36.94	24.33	11	9403	952	63478656
Tuberculosis gastrointestinal	36.89	24.33	9	9405	364	63479244
Liver transplant	34.73	24.33	13	9401	2278	63477330
Vomiting	34.59	24.33	169	9245	559448	62920160
Lymph node tuberculosis	34.48	24.33	10	9404	789	63478819
Psychotic disorder	33.69	24.33	29	9385	25683	63453925
Hypertransaminasaemia	32.50	24.33	17	9397	6592	63473016
Joint swelling	32.32	24.33	5	9409	327661	63151947
Anaemia	32.11	24.33	106	9308	293324	63186284
Hepatic necrosis	31.95	24.33	16	9398	5671	63473937
Immune system disorder	31.25	24.33	19	9395	9815	63469793
Pathogen resistance	30.17	24.33	16	9398	6382	63473226
Peritoneal tuberculosis	29.59	24.33	8	9406	488	63479120
Herbal toxicity	29.22	24.33	5	9409	31	63479577
Respiratory failure	28.72	24.33	53	9361	101805	63377803
Coagulopathy	28.61	24.33	24	9390	20520	63459088
Infectious pleural effusion	27.76	24.33	10	9404	1573	63478035
Exposure during pregnancy	27.62	24.33	67	9347	155480	63324128
Swelling	27.61	24.33	4	9410	275374	63204234
Pain in extremity	26.72	24.33	8	9406	331478	63148130
Optic neuritis	26.04	24.33	16	9398	8419	63471189
Mastitis bacterial	26.04	24.33	5	9409	63	63479545
Ototoxicity	25.38	24.33	9	9405	1353	63478255
Generalised tonic-clonic seizure	25.10	24.33	26	9388	28990	63450618
Pseudomembranous colitis	24.35	24.33	11	9403	3101	63476507

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Paradoxical drug reaction	915.43	20.48	215	11631	3136	34941949
Immune reconstitution inflammatory syndrome	506.09	20.48	166	11680	8593	34936492
Drug-induced liver injury	442.62	20.48	209	11637	28623	34916462
Drug reaction with eosinophilia and systemic symptoms	424.57	20.48	212	11634	32800	34912285
Hepatotoxicity	327.23	20.48	155	11691	21330	34923755
Immune reconstitution inflammatory syndrome associated tuberculosis	268.15	20.48	55	11791	403	34944682
Drug resistance	243.30	20.48	135	11711	25792	34919293
Jaundice	217.38	20.48	135	11711	31747	34913338
Tuberculosis	171.92	20.48	75	11771	8502	34936583
Tuberculoma of central nervous system	168.11	20.48	34	11812	230	34944855
Hepatitis	144.84	20.48	94	11752	23810	34921275
Pulmonary tuberculosis	113.24	20.48	47	11799	4707	34940378
Acute hepatic failure	101.93	20.48	62	11784	14012	34931073
Meningitis tuberculous	101.68	20.48	27	11819	658	34944427
Immune system disorder	90.50	20.48	41	11805	5074	34940011
Tuberculosis of central nervous system	87.52	20.48	19	11827	188	34944897
Hydrocephalus	86.48	20.48	40	11806	5192	34939893
Electrocardiogram QT prolonged	84.97	20.48	86	11760	40866	34904219
Drug interaction	77.17	20.48	208	11638	225738	34719347
Lymphadenopathy	76.56	20.48	69	11777	28394	34916691
Disseminated tuberculosis	70.63	20.48	27	11819	2178	34942907
Drug level decreased	63.13	20.48	37	11809	7809	34937276
Optic neuropathy	62.72	20.48	24	11822	1941	34943144
Pyrexia	60.10	20.48	247	11599	332766	34612319
Granuloma	57.32	20.48	26	11820	3225	34941860
Skin disorder	55.60	20.48	42	11804	13513	34931572
Multiple-drug resistance	51.03	20.48	28	11818	5211	34939874
Liver function test abnormal	49.88	20.48	57	11789	31017	34914068
Optic neuritis	48.91	20.48	24	11822	3550	34941535
Alanine aminotransferase increased	48.27	20.48	93	11753	80722	34864363
Hepatic failure	48.25	20.48	59	11787	34472	34910613
Death	47.89	20.48	39	11807	398010	34547075
Eosinophilia	45.34	20.48	50	11796	26172	34918913
Neuropathy peripheral	45.12	20.48	92	11754	83171	34861914
Granulomatous liver disease	45.07	20.48	14	11832	603	34944482
Lymph node tuberculosis	44.53	20.48	13	11833	452	34944633
Hepatic enzyme increased	43.99	20.48	60	11786	39020	34906065
Diaphragmatic injury	43.85	20.48	10	11836	126	34944959
Hepatitis toxic	42.58	20.48	19	11827	2268	34942817
Mycobacterial infection	41.90	20.48	19	11827	2355	34942730
Splenic embolism	40.06	20.48	10	11836	189	34944896
Hepatitis fulminant	39.73	20.48	22	11824	4168	34940917
Tubulointerstitial nephritis	39.69	20.48	42	11804	20982	34924103
Central nervous system vasculitis	39.09	20.48	12	11834	497	34944588
Tuberculosis gastrointestinal	38.04	20.48	10	11836	234	34944851
Sideroblastic anaemia	37.45	20.48	10	11836	249	34944836
Pain	36.45	20.48	12	11834	204663	34740422
Aspartate aminotransferase increased	35.65	20.48	74	11772	67709	34877376
Toxic epidermal necrolysis	35.23	20.48	40	11806	21606	34923479
Tuberculosis of eye	34.91	20.48	7	11839	45	34945040
Vitamin B1 decreased	34.81	20.48	10	11836	328	34944757
Thalamic infarction	34.04	20.48	12	11834	769	34944316
Oral candidiasis	33.81	20.48	30	11816	12080	34933005
Deafness	33.65	20.48	29	11817	11236	34933849
Transaminases increased	32.96	20.48	43	11803	26780	34918305
Fall	32.60	20.48	14	11832	202871	34742214
Unmasking of previously unidentified disease	32.20	20.48	12	11834	902	34944183
Mitochondrial neurogastrointestinal encephalopathy	32.02	20.48	5	11841	4	34945081
Lymphopenia	31.48	20.48	33	11813	16302	34928783
Condition aggravated	30.22	20.48	137	11709	192059	34753026
Tuberculous pleurisy	29.17	20.48	9	11837	379	34944706
Bone tuberculosis	28.75	20.48	9	11837	398	34944687
Brain oedema	28.58	20.48	29	11817	13792	34931293
Pathogen resistance	27.49	20.48	24	11822	9458	34935627
Hyperuricaemia	26.69	20.48	22	11824	8021	34937064
Ototoxicity	26.61	20.48	13	11833	1904	34943181
Urinary tract inflammation	26.42	20.48	7	11839	169	34944916
Vomiting	25.50	20.48	157	11689	247464	34697621
Fatigue	25.40	20.48	55	11791	370598	34574487
Psoas abscess	25.14	20.48	9	11837	603	34944482
Drug eruption	24.60	20.48	32	11814	19866	34925219
Pulmonary sequestration	23.98	20.48	5	11841	40	34945045
Rash maculo-papular	23.79	20.48	38	11808	28413	34916672
Implant site infection	23.36	20.48	10	11836	1080	34944005
Lichenoid keratosis	23.32	20.48	13	11833	2495	34942590
Pulmonary granuloma	23.13	20.48	11	11835	1519	34943566
Splenomegaly	23.02	20.48	27	11819	15090	34929995
Marrow hyperplasia	22.74	20.48	10	11836	1153	34943932
Constipation	22.71	20.48	9	11837	136973	34808112
Renal atrophy	22.56	20.48	10	11836	1175	34943910
Type III immune complex mediated reaction	22.48	20.48	7	11839	304	34944781
Dilatation intrahepatic duct acquired	22.15	20.48	5	11841	60	34945025
Tuberculoid leprosy	22.07	20.48	5	11841	61	34945024
Atrial fibrillation	22.07	20.48	7	11839	122386	34822699
Chronic allograft nephropathy	21.99	20.48	10	11836	1247	34943838
Trisomy 21	21.76	20.48	8	11838	579	34944506
Jarisch-Herxheimer reaction	21.70	20.48	8	11838	583	34944502
Optic atrophy	21.64	20.48	9	11837	905	34944180
HIV infection	21.39	20.48	10	11836	1329	34943756
Hereditary optic atrophy	21.33	20.48	4	11842	17	34945068
Product dose omission issue	21.32	20.48	7	11839	119704	34825381
Febrile neutropenia	21.09	20.48	10	11836	136839	34808246
Splenic abscess	21.06	20.48	7	11839	375	34944710
Protrusion tongue	21.00	20.48	6	11840	193	34944892
Autoimmune haemolytic anaemia	20.84	20.48	15	11831	4481	34940604
Pancytopenia	20.63	20.48	75	11771	95082	34850003

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Paradoxical drug reaction	1361.61	18.97	326	20383	6859	79716820
Drug reaction with eosinophilia and systemic symptoms	1134.15	18.97	474	20235	63770	79659909
Drug-induced liver injury	752.43	18.97	359	20350	65758	79657921
Immune reconstitution inflammatory syndrome	710.55	18.97	225	20484	13616	79710063
Hepatotoxicity	536.04	18.97	263	20446	51089	79672590
Drug resistance	528.45	18.97	245	20464	41968	79681711
Immune reconstitution inflammatory syndrome associated tuberculosis	471.00	18.97	93	20616	743	79722936
Acute hepatic failure	457.04	18.97	200	20509	29913	79693766
Tuberculoma of central nervous system	390.17	18.97	75	20634	512	79723167
Jaundice	367.51	18.97	207	20502	53142	79670537
Hepatitis	271.31	18.97	173	20536	55554	79668125
Tuberculosis	250.30	18.97	107	20602	15091	79708588
Pulmonary tuberculosis	234.13	18.97	85	20624	7780	79715899
Drug interaction	189.53	18.97	365	20344	414818	79308861
Meningitis tuberculous	159.24	18.97	41	20668	1164	79722515
Neuropathy peripheral	149.88	18.97	184	20525	141121	79582558
Pyrexia	135.88	18.97	435	20274	678274	79045405
Electrocardiogram QT prolonged	135.61	18.97	141	20568	90245	79633434
Lymphadenopathy	134.25	18.97	111	20598	53136	79670543
Disseminated tuberculosis	131.20	18.97	47	20662	4136	79719543
Hepatic encephalopathy	124.96	18.97	78	20631	24088	79699591
Immune system disorder	122.43	18.97	59	20650	10970	79712709
Eosinophilia	119.49	18.97	97	20612	45248	79678431
Alanine aminotransferase increased	119.35	18.97	177	20532	162393	79561286
Drug level decreased	113.12	18.97	61	20648	14341	79709338
Hydrocephalus	109.16	18.97	51	20658	8849	79714830
Optic neuropathy	108.72	18.97	39	20670	3445	79720234
Aspartate aminotransferase increased	97.52	18.97	148	20561	138493	79585186
Tuberculosis of central nervous system	91.36	18.97	22	20687	471	79723208
Hepatic failure	87.33	18.97	93	20616	61119	79662560
Hepatitis toxic	87.24	18.97	37	20672	5110	79718569
Pain	82.49	18.97	40	20669	703762	79019917
Lymph node tuberculosis	80.08	18.97	23	20686	991	79722688
Pancreatitis haemorrhagic	79.99	18.97	22	20687	808	79722871
Transaminases increased	79.86	18.97	82	20627	51661	79672018
Fall	77.83	18.97	16	20693	487613	79236066
Hepatitis fulminant	75.05	18.97	37	20672	7225	79716454
Multiple-drug resistance	73.93	18.97	39	20670	8769	79714910
Optic neuritis	71.08	18.97	39	20670	9481	79714198
Tuberculosis gastrointestinal	68.44	18.97	18	20691	556	79723123
Fatigue	67.26	18.97	86	20623	929641	78794038
Granuloma	61.98	18.97	34	20675	8263	79715416
Rash maculo-papular	60.94	18.97	74	20635	56004	79667675
Granulomatous liver disease	53.48	18.97	18	20691	1315	79722364
Liver function test abnormal	51.31	18.97	73	20636	64402	79659277
Distributive shock	51.20	18.97	21	20688	2666	79721013
Skin disorder	50.94	18.97	53	20656	33890	79689789
Immunosuppressant drug level decreased	49.88	18.97	19	20690	1985	79721694
Sideroblastic anaemia	49.31	18.97	12	20697	269	79723410
Hepatocellular injury	48.80	18.97	61	20648	47532	79676147
Vomiting	48.56	18.97	317	20392	665511	79058168
Liver transplant	47.09	18.97	23	20686	4400	79719279
Peritoneal tuberculosis	46.59	18.97	13	20696	504	79723175
Diaphragmatic injury	46.50	18.97	10	20699	126	79723553
Mycobacterial infection	44.92	18.97	21	20688	3647	79720032
Hepatic function abnormal	44.37	18.97	73	20636	73034	79650645
Ototoxicity	44.02	18.97	20	20689	3254	79720425
Blood pressure increased	43.23	18.97	3	20706	211357	79512322
Joint swelling	42.95	18.97	11	20698	288635	79435044
Jarisch-Herxheimer reaction	42.69	18.97	14	20695	943	79722736
Splenic embolism	42.08	18.97	10	20699	202	79723477
Pathogen resistance	40.57	18.97	32	20677	14310	79709369
Anaemia	39.43	18.97	223	20486	444792	79278887
Sinusitis	39.34	18.97	3	20706	195498	79528181
Completed suicide	39.29	18.97	8	20701	245759	79477920
Hyperuricaemia	39.26	18.97	29	20680	11770	79711909
Cholestatic liver injury	38.99	18.97	21	20688	4920	79718759
Peripheral swelling	38.74	18.97	11	20698	269606	79454073
Death	38.21	18.97	55	20654	566459	79157220
Liver transplant rejection	37.94	18.97	18	20691	3230	79720449
Pain in extremity	37.85	18.97	24	20685	364514	79359165
Product dose omission issue	37.66	18.97	9	20700	247528	79476151
Psychotic disorder	37.64	18.97	50	20659	41352	79682327
Central nervous system vasculitis	37.40	18.97	14	20695	1394	79722285
Deafness	37.36	18.97	36	20673	21001	79702678
Rheumatoid arthritis	37.29	18.97	5	20704	208465	79515214
Oedematous kidney	36.72	18.97	9	20700	208	79723471
HIV infection	36.61	18.97	13	20696	1114	79722565
Bone tuberculosis	36.35	18.97	11	20698	569	79723110
Toxic optic neuropathy	36.32	18.97	13	20696	1140	79722539
Toxic epidermal necrolysis	34.76	18.97	50	20659	44531	79679148
Thalamic infarction	34.73	18.97	13	20696	1294	79722385
Febrile neutropenia	33.98	18.97	9	20700	230990	79492689
Gamma-glutamyltransferase increased	33.72	18.97	55	20654	54625	79669054
Brain oedema	33.59	18.97	37	20672	25226	79698453
Blood bilirubin increased	33.47	18.97	61	20648	66171	79657508
Constipation	33.19	18.97	16	20693	283034	79440645
Tuberculosis of eye	33.10	18.97	7	20702	81	79723598
Haemolytic anaemia	32.60	18.97	31	20678	17789	79705890
Oedematous pancreatitis	32.44	18.97	12	20697	1156	79722523
Vitamin B1 decreased	32.40	18.97	10	20699	553	79723126
Arthropathy	32.27	18.97	4	20705	177107	79546572
Unmasking of previously unidentified disease	32.26	18.97	14	20695	2043	79721636
Splenomegaly	32.21	18.97	33	20676	20721	79702958
Face oedema	31.98	18.97	38	20671	28098	79695581
Splenic abscess	31.84	18.97	10	20699	586	79723093
Hepatic necrosis	31.71	18.97	23	20686	9077	79714602
Polyneuropathy	31.47	18.97	35	20674	24116	79699563
Tubulointerstitial nephritis	31.46	18.97	44	20665	38191	79685488
Lichenoid keratosis	31.34	18.97	17	20692	4040	79719639
Lymphopenia	31.06	18.97	39	20670	30518	79693161
Disseminated intravascular coagulation	30.62	18.97	42	20667	35800	79687879
Weight increased	30.56	18.97	17	20692	277369	79446310
Feeling abnormal	30.51	18.97	3	20706	159196	79564483
Mitochondrial neurogastrointestinal encephalopathy	30.17	18.97	5	20704	12	79723667
Cachexia	29.79	18.97	24	20685	11059	79712620
Musculoskeletal stiffness	29.45	18.97	5	20704	175003	79548676
Hypertension	28.95	18.97	26	20683	330966	79392713
Back pain	28.95	18.97	22	20687	304158	79419521
Hypertransaminasaemia	28.25	18.97	24	20685	11900	79711779
COVID-19	27.68	18.97	4	20705	157670	79566009
Oral candidiasis	27.26	18.97	36	20673	29592	79694087
Pulmonary sequestration	26.85	18.97	5	20704	28	79723651
Hepatic enzyme increased	26.77	18.97	106	20603	182504	79541175
Psoas abscess	26.61	18.97	10	20699	1007	79722672
Anxiety	26.28	18.97	16	20693	248496	79475183
Synovitis	26.05	18.97	4	20705	150730	79572949
Hepatomegaly	25.71	18.97	28	20681	18846	79704833
Hereditary optic atrophy	25.53	18.97	5	20704	38	79723641
Encephalopathy	25.51	18.97	55	20654	67342	79656337
Aspergillus infection	25.36	18.97	28	20681	19133	79704546
Atrial fibrillation	25.06	18.97	10	20699	197876	79525803
Infection	24.95	18.97	16	20693	241696	79481983
Granulomatous lymphadenitis	24.73	18.97	7	20702	286	79723393
Liver injury	24.72	18.97	49	20660	56565	79667114
Hyperbilirubinaemia	24.45	18.97	31	20678	24487	79699192
Abdominal discomfort	24.02	18.97	18	20691	250709	79472970
Condition aggravated	23.76	18.97	216	20493	500908	79222771
Lymph node abscess	23.71	18.97	5	20704	57	79723622
Urinary tract infection	23.48	18.97	22	20687	274490	79449189
Injection site pain	23.48	18.97	3	20706	129835	79593844
Influenza	23.43	18.97	3	20706	129603	79594076
Transplant rejection	23.34	18.97	27	20682	19410	79704269
Pancytopenia	23.32	18.97	95	20614	165650	79558029
Coagulopathy	23.26	18.97	37	20672	35969	79687710
Drug hypersensitivity	23.25	18.97	26	20683	298890	79424789
Mastitis bacterial	23.25	18.97	5	20704	63	79723616
Tuberculous pleurisy	23.07	18.97	8	20701	639	79723040
Stomatitis	22.98	18.97	5	20704	146752	79576927
Therapeutic product effect decreased	22.95	18.97	7	20702	163856	79559823
Oligohydramnios	22.81	18.97	13	20696	3399	79720280
Diarrhoea	22.73	18.97	135	20574	880354	78843325
Testicular mass	22.63	18.97	5	20704	72	79723607
Pulmonary granuloma	22.49	18.97	11	20698	2110	79721569
Discomfort	22.48	18.97	3	20706	125614	79598065
Rash morbilliform	22.47	18.97	16	20693	6134	79717545
Marrow hyperplasia	21.94	18.97	10	20699	1638	79722041
Alopecia	21.66	18.97	17	20692	231338	79492341
Chylothorax	21.66	18.97	8	20701	767	79722912
Cutaneous tuberculosis	21.64	18.97	6	20703	227	79723452
Chronic allograft nephropathy	21.58	18.97	10	20699	1701	79721978
Arachnoiditis	21.58	18.97	8	20701	775	79722904
Subacute hepatic failure	21.54	18.97	6	20703	231	79723448
Contusion	21.49	18.97	6	20703	148770	79574909
Swelling	21.49	18.97	15	20694	216696	79506983
Adrenocortical insufficiency acute	21.44	18.97	12	20697	3031	79720648
Mycobacterium abscessus infection	21.42	18.97	9	20700	1213	79722466
Conductive deafness	21.34	18.97	6	20703	239	79723440
Urinary tract inflammation	20.99	18.97	6	20703	254	79723425
Renal atrophy	20.97	18.97	10	20699	1815	79721864
Tuberculoid leprosy	20.76	18.97	5	20704	107	79723572
Implant site infection	20.76	18.97	10	20699	1855	79721824
Overdose	20.70	18.97	11	20698	184195	79539484
Herbal toxicity	20.59	18.97	4	20705	29	79723650
Drug intolerance	20.51	18.97	23	20686	264096	79459583
Generalised tonic-clonic seizure	20.38	18.97	39	20670	43871	79679808
Wheezing	20.38	18.97	3	20706	116661	79607018
Headache	20.35	18.97	94	20615	653678	79070001
Encephalitis	20.28	18.97	22	20687	14738	79708941
Contraindicated product administered	19.88	18.97	8	20701	157530	79566149
Phosphorus metabolism disorder	19.69	18.97	3	20706	3	79723676
Ascites	19.31	18.97	53	20656	75509	79648170
Clostridium difficile colitis	19.26	18.97	32	20677	32251	79691428
Thrombocytopenia	19.05	18.97	126	20583	265133	79458546

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J04AK01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Other drugs for treatment of tuberculosis
ATC	J04AM05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
ATC	J04AM06	ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF TUBERCULOSIS Combinations of drugs for treatment of tuberculosis
FDA EPC	N0000175483	Antimycobacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000995	Antitubercular Agents
CHEBI has role	CHEBI:33231	antitubercular agents
CHEBI has role	CHEBI:50266	Prodrugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute tuberculosis	indication	25629007
Tuberculosis of meninges	indication	58437007
Pulmonary tuberculosis	indication	154283005	DOID:2957
Nutritional disorder	contraindication	2492009	DOID:374
Alcoholism	contraindication	7200002
Jaundice	contraindication	18165001
Acute hepatitis	contraindication	37871000
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Diabetes mellitus	contraindication	73211009	DOID:9351
Gout	contraindication	90560007	DOID:13189
Anemia due to enzyme deficiency	contraindication	111577008
Acute hepatic failure	contraindication	197270009
Disease of liver	contraindication	235856003	DOID:409
Diabetic - poor control	contraindication	268519009
Peripheral nerve disease	contraindication	302226006
Porphyria	contraindication	418470004
Diabetic peripheral neuropathy	contraindication	424736006
Slow acetylator due to N-acetyltransferase enzyme variant	contraindication	425079005
Chronic Hepatic Disease	contraindication
Prolonged-Severe Nausea and Vomiting	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.39	acidic
pKa2	2.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	6.89	WOMBAT-PK
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		IC50	5.77	WOMBAT-PK
Cytochrome P450 3A5	Enzyme	P20815	CP3A5_HUMAN		IC50	4.89	WOMBAT-PK
3-oxoacyl-ACP synthase; Fatty acid synthase Fas; Probable fatty acid synthase Fas (Fatty acid synthetase)	Enzyme		P95029_MYCTU	INHIBITOR			CHEMBL	CHEMBL
Cyclopropane mycolic acid synthase 1	Enzyme		CMAS1_MYCTO				WOMBAT-PK
Amidase; Nicotinamidase; Nicotinamidase/pyrazinamidase; Pyrazinamidase; Pyrazinamidase/nicotinamidase; Pyrazinamidase/nicotinamidase PncA	Enzyme		Q50575_MYCTX				WOMBAT-PK

External reference:

ID	Source
4017915	VUID
N0000146266	NUI
D00144	KEGG_DRUG
4017915	VANDF
C0034239	UMLSCUI
CHEBI:45285	CHEBI
PZA	PDB_CHEM_ID
CHEMBL614	ChEMBL_ID
1046	PUBCHEM_CID
DB00339	DRUGBANK_ID
D011718	MESH_DESCRIPTOR_UI
786	INN_ID
7287	IUPHAR_LIGAND_ID
2KNI5N06TI	UNII
8987	RXNORM
2368	MMSL
5390	MMSL
d00117	MMSL
002849	NDDF
13592004	SNOMEDCT_US
387076005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6696	TABLET	500 mg	ORAL	ANDA	21 sections
PYRAZINAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	10135-735	TABLET	500 mg	ORAL	ANDA	22 sections
Pyrazinamide	Human Prescription Drug Label	1	33342-447	TABLET	500 mg	ORAL	ANDA	21 sections
Pyrazinamide	Human Prescription Drug Label	1	33342-447	TABLET	500 mg	ORAL	ANDA	21 sections
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0520	TABLET	500 mg	ORAL	ANDA	22 sections
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0520	TABLET	500 mg	ORAL	ANDA	22 sections
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0521	TABLET	500 mg	ORAL	ANDA	21 sections
Pyrazinamide	Human Prescription Drug Label	1	50090-5963	TABLET	500 mg	ORAL	ANDA	21 sections
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	55695-026	TABLET	500 mg	ORAL	ANDA	22 sections
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	61748-012	TABLET	500 mg	ORAL	ANDA	22 sections
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	61748-012	TABLET	500 mg	ORAL	ANDA	22 sections
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	67253-660	TABLET	500 mg	ORAL	ANDA	21 sections
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2534	TABLET	500 mg	ORAL	ANDA	22 sections
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2534	TABLET	500 mg	ORAL	ANDA	22 sections
Pyrazinamide	HUMAN PRESCRIPTION DRUG LABEL	1	70518-3661	TABLET	500 mg	ORAL	ANDA	21 sections
Pyrazinamide	Human Prescription Drug Label	1	70954-484	TABLET	500 mg	ORAL	ANDA	21 sections